Ultragenyx Pharmaceutical Inc.
For the period ended May 14, 2026. Filed Mar 27, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 14, 2026 · Filed Mar 27, 2026
Contents
Proxy Statement Overview
This overview highlights certain information contained elsewhere in this Proxy Statement and does not contain all of the information that you should consider. You should read the entire Proxy Statement carefully before voting. For more complete information regarding our business and 2025 performance, please review our 2025 Annual Report on Form 10-K as filed with the U.S. Securities and Exchange Commission (SEC) in February 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.